Clinical trial · Interventional
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity: a Prospective Randomized Open Label Clinical Trial
NCT04030546CI-TRIAL-00042410unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients With Cancer | Malignant Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ivabradine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Ivabradine
- description
- Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until the last chemotherapy session
- interventionNames
- Drug: Ivabradine
- type
- NO_INTERVENTION
- label
- Usual care
- description
- Patient will receive usual care
Primary outcomes (1)
- measure
- Change in left venticular dysfunction by global longitudinal strain (GLS).
- timeFrame
- 1, 3 and 6 months
- description
- Change in global longitudinal strain (GLS) at least by 3%.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * cancer patients undergoing anthracyclines based chemotherapy; * heart rate (HR) \> 70 times per minute; * Written informed consent. Exclusion Criteria: * Contraindications for ivabradine administration; * HR\<70 times per minute; * Incapability to complete informed consent; * Severe valve disease; * Left ventricular ejection fraction (LVEF)≤ 30 %; * Other severe conditions; * Poor echogenicity.
References
Publications (0)
Data not yet available
No reference posted for this study.